Neuralstem, Inc. Form 8-K August 02, 2013

Rockville, Maryland 20850

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549					
FORM 8-K					
CURRENT REPORT					
Pursuant to Section 13 or 15(d)	of the				
Securities Exchange Act of 1934					
Date of report (Date of earliest	event reported): August	2, 2013 (August 1, 2013)			
Neuralstem, Inc.					
(Exact name of registrant as sp	ecified in Charter)				
Delaware (State or other jurisdiction of incorporation or organization)	000-1357459 (Commission File No.)	52-2007292 (IRS Employee Identification No.)			
9700 Great Seneca Highway,					

Edgar Filing: Neuralstem, Inc. - Form 8-K

(Address of Principal Executive Offices)	
(301) 366-4841	
(Issuer Telephone number)	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: Neuralstem, Inc. - Form 8-K

Item 8.01.

Other Events.

On August 1, 2013, Neuralstem, Inc. ("Company") announced that a paper published in the journal "Cell Transplantation – The Regenerative Medicine Journal," reported that the Company's spinal cord-derived neural stem cells, NSI-566, improved cognitive function in rats who'd received radiation to the brain as assessed by two separate cognitive tasks. A copy of the press release is attached to this report as Exhibit 99.01.

Item 9.01

Financial Statement and Exhibits.

Exhibit Number Description

99.01 Press Release Dated August 1, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By: /s/ I. Richard Garr I. Richard Garr

Chief Executive Officer

Dated: August 2, 2013

Edgar Filing: Neuralstem, Inc. - Form 8-K

INDEX OF EXHIBITS

Exhibit Number Description

99.01 Press Release Dated August 1, 2013